Abstract
In 2021, the COVID-19 pandemic continues to challenge the globalized world. Restrictions on the public life and lockdowns of different characteristics define the life in many countries. This paper focuses on the first year of the COVID-19 pandemic (01-28-2020 to 01-15-2021). As a transfer of methods used in reliability engineering for analyzing occurrence of infection, Weibull distribution models are used to evaluate the spreading behavior of COVID-19.
Key issues of this study are the differences of spreading behavior in first and second pandemic phase and the various impacts of lockdown measures with different characteristics (hard, light). Therefore, the occurrence of infection in normed time periods with and without lockdown measures are analyzed in detail on the example of Germany representing the spreading behavior in Europe. Additional information in comparison to classical infection analyzes models like SIR model is generated by the application of Weibull distribution models with easy interpretable parameters and the dynamic development of COVID-19 is outlined.
In a further step, the occurrence of infection of COVID-19 is put into the context of other common infectious diseases in Germany like Influenza or Norovirus to evaluate the infectiousness. Differences in spreading behavior of COVID-19 in comparison to these well-known infectious diseases are underlined for different pandemic phases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Wuppertal, Germany
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: bracke{at}uni-wuppertal.de
Data Availability
Base of operations is the COVID-19 data base from Johns Hopkins University (JHU)
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
